Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study

Frizziero, Luisa; Calciati, Andrea; Torresin, Tommaso; Midena, Giulia; Parrozzani, Raffaele; Pilotto, Elisabetta; Midena, Edoardo

doi:10.3390/jpm11050405

Open AccessArticle

Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study

by

Luisa Frizziero

¹

,

Andrea Calciati

¹,

Tommaso Torresin

¹

,

Giulia Midena

²

,

Raffaele Parrozzani

¹,

Elisabetta Pilotto

¹ and

Edoardo Midena

^1,2,*

¹

Department of Neuroscience—Ophthalmology, University of Padova, 35128 Padova, Italy

²

IRCCS—Fondazione Bietti, 00120 Rome, Italy

^*

Author to whom correspondence should be addressed.

J. Pers. Med. 2021, 11(5), 405; https://doi.org/10.3390/jpm11050405

Submission received: 19 April 2021 / Revised: 10 May 2021 / Accepted: 11 May 2021 / Published: 13 May 2021

(This article belongs to the Special Issue Age-Related Macular Degeneration and Diabetic Retinopathy)

Download

Browse Figure

Versions Notes

Abstract

The aim of this study was to evaluate the long-term efficacy and safety of 577-nm subthreshold micropulse laser (SMPL) treatment in a large population of patients affected by mild diabetic macular edema (DME) in a real-life setting. We retrospectively evaluated 134 eyes affected by previously untreated center-involving mild DME, and treated with 577-nm SMPL, using fixed parameters. Retreatment was performed at 3 months, in case of persistent retinal thickening. Optical coherence tomography (OCT), along with short and near-infrared fundus autofluorescence, were used to confirm long-term safety. At the end of at least one year follow-up, a significant improvement in visual acuity was documented, compared to baseline (77.3 ± 4.5 and 79.4 ± 4.4 ETDRS score at baseline and at final follow-up, respectively), as well as a reduction in the mean retinal thickness of the thickest ETDRS macular sector at baseline. A reduction in the central retinal thickness and the mean thickness of the nine ETDRS sectors was also found, without reaching statistical significance. No patients required intravitreal injections. No adverse effects were detected. This study suggests that 577-nm SMPL is a safe and repeatable treatment for mild DME that may be applied to real-life clinical settings using fixed parameters and protocols.

Keywords: subthreshold micropulse laser; 577-nm laser; laser fixed parameters; diabetic retinopathy; diabetic macular edema; optical coherence tomography; autofluorescence; real-life

Share and Cite

MDPI and ACS Style

Frizziero, L.; Calciati, A.; Torresin, T.; Midena, G.; Parrozzani, R.; Pilotto, E.; Midena, E. Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study. J. Pers. Med. 2021, 11, 405. https://doi.org/10.3390/jpm11050405

AMA Style

Frizziero L, Calciati A, Torresin T, Midena G, Parrozzani R, Pilotto E, Midena E. Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study. Journal of Personalized Medicine. 2021; 11(5):405. https://doi.org/10.3390/jpm11050405

Chicago/Turabian Style

Frizziero, Luisa, Andrea Calciati, Tommaso Torresin, Giulia Midena, Raffaele Parrozzani, Elisabetta Pilotto, and Edoardo Midena. 2021. "Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study" Journal of Personalized Medicine 11, no. 5: 405. https://doi.org/10.3390/jpm11050405

APA Style

Frizziero, L., Calciati, A., Torresin, T., Midena, G., Parrozzani, R., Pilotto, E., & Midena, E. (2021). Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study. Journal of Personalized Medicine, 11(5), 405. https://doi.org/10.3390/jpm11050405

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Diabetic Macular Edema Treated with 577-nm Subthreshold Micropulse Laser: A Real-Life, Long-Term Study

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI